Alan Meng retweeted
Immune cells continually detect, engulf, and destroy invasive microbes and cancer cells.
This process, called phagocytosis, is carried out by macrophages that must distinguish between proengulfment signals and inhibitory (“don’t-eat-me”) warnings. Cluster of differentiation 47 (CD47), a cell-surface receptor, is the archetypal don’t-eat-me signal. Many cancers upregulate CD47 expression to escape phagocytosis, and CD47 blockade promotes phagocytosis of cancer cells in mice.
However, CD47 blockers have not shown clinical benefits in patients with acute myeloid leukemia (AML), an aggressive cancer of blood immune cells. This discrepancy has raised the possibility that the molecular programs that inhibit phagocytosis differ between mice and humans.
In a new Science study, researchers report that the mechanisms that control macrophage function in human and mouse cells are indeed different. They also identify cluster of differentiation 43 (CD43) as a potential target for human AML treatment.
Learn more in a new #SciencePerspective: scim.ag/48fISiT
Alan Meng retweeted
We often use PD-L1 or CD8 density to predict response to #immunotherapy
But this study suggests something else may matter more: DISTANCE
In resectable NSCLC treated with neoadjuvant chemoimmunotherapy (multiplex spatial analysis, n=44), response was best predicted by how close PD-1 CD8 tissue resident memory T cells (TRM) were to PD-L1+ tumor cells.
AUC 0.74
OR 8.83 (p=0.007)
Interestingly, this spatial interaction within the tumor microenvironment also correlated with HIF-1 CD8 T cells, linking immune proximity, tumor hypoxia and response.
tlcr.amegroups.org/article/v… @OncoAlert #NSCLC #lcsm #LungCancer #LungCancerResearch
Alan Meng retweeted
🚨 Upper GI at #GI26: Challenging the Throne 👑
Gastric and esophageal cancers are the most unstable battlefield in oncology right now.
Old standards are under pressure. New kings are knocking.
Here is your roadmap to the decisive battles 👇
👑 The Main Event: HER2+ First Line
LBA285 (HERIZON-GEA-01)
Zanidatamab + chemotherapy ± tislelizumab
vs
Trastuzumab + chemotherapy
This is not an add-on question.
This is a replacement question.
If a bispecific beats a 15-year standard, the entire HER2 algorithm flips overnight ⚔️
⚔️ The Peri-operative Power Struggle
MATTERHORN and KEYNOTE-585 updates
Everyone is hunting for the same thing: overall survival to lock FLOT + immunotherapy as global standard 🧬
ESOPEC discussions continue to ripple
FLOT vs CROSS in esophageal adenocarcinoma is far from settled ⚖️
🎯 New Targets Tighten the Net
Cadonilimab (PD-1/CTLA-4) + chemotherapy
Long-term follow-up data, durability under the microscope 🔍
Zolbetuximab
CLDN18.2 moves from trial success to real-world execution 🎯
💡 My Take
LBA285 is the readout of the meeting.
If Zanidatamab wins, we are not optimizing therapy.
We are changing the backbone.
#GI26 #StomachCancer #EsophagealCancer #OncTwitter #MedEd
@myesmo @asco @esmo_open @OncoAlert
Top 10 #ASCOGI26 trials to look out for 🔥🧬
1️⃣ HERIZON-GEA-01
Phase III zanidatamab based combinations in HER2 positive gastric and GEJ adenocarcinoma. Strong first line OS and PFS signal.
2️⃣ ILUSTRO
Zolbetuximab plus chemotherapy with or without immunotherapy in CLDN18.2 positive HER2 negative gastric and GEJ cancer.
3️⃣ LUCERNA
Zolbetuximab combined with chemotherapy and PD-1 blockade in CLDN18.2 positive PD-L1 positive gastric cancer.
4️⃣ ACCENT
Narmafotinib with gemcitabine and nab-paclitaxel in metastatic pancreatic ductal adenocarcinoma. Updated phase II efficacy and safety.
5️⃣ PT886-101
Spevatamig plus standard chemotherapy as first line treatment in metastatic pancreatic cancer. Early phase signal generating study.
6️⃣ ASP3082-001
First in human KRAS G12D degrader program in advanced solid tumors including pancreatic cancer.
7️⃣ TIGeR-PaC
Targeted intra-arterial delivery of chemotherapy for locally advanced and metastatic pancreatic cancer.
8️⃣ CIRCULATE-GI
ctDNA guided adjuvant and surveillance strategy across colorectal and other GI malignancies.
9️⃣ CHALLENGE-CRC
Structured exercise intervention trial evaluating disease free survival and quality of life in colorectal cancer survivors.
🔟 DISCO-NET
Next generation somatostatin receptor imaging trial comparing novel PET tracers in neuroendocrine tumors.
@ASCO @ConquerCancerFd @OncoAlert @Larvol
Alan Meng retweeted
🚨 Trials to Watch – WCLC 2025 🚨
🔑 Plenary LBAs:
FLAURA2: Osimertinib + Chemo (OS update)
Aumolertinib + Chemo (EGFRm NSCLC)
HARMONi-A: Ivonescimab + Chemo vs Chemo
ARROS-1: Zidesamtinib (ROS1+)
CheckMate 816: Neoadjuvant Nivolumab (OS)
EA5181: Durvalumab + CRT in Stage III
NADIM Adjuvant: Nivolumab + Chemo
Oncology is moving fast—practice-changing data ahead!
#WCLC25 @OncoAlert @OncBrothers @medicalwatchBC
Alan Meng retweeted
Review:
Regulatory T cells in solid tumor immunotherapy: effect, mechanism and clinical application
nature.com/articles/s41419-0…
Alan Meng retweeted
📢Happy to share our @NatRevImmunol article; Result of excellent #collaboration with @deadoc80 @AdrianListon & K Smith!
📑Read here: rdcu.be/ehm67
🔥Take🏠msg: Time to move away from narrow concept of #exhausted T cells to other #states!
1/6🧵
@OncoDailyIO @oncodaily
Alan Meng retweeted
Pancreatic cancer
💥Great review
(We could discuss the median OS of 4 months (?) mentioned in the first sentence)
thelancet.com/journals/lance…
Alan Meng retweeted
No other class of anticancer drug comes close to the number of cures that can be attributed to chemotherapy.
Yet, our understanding of how it truly works is extremely limited.
This perspective on the topic is a must read.
Including for ADC enthusiasts.
nature.com/articles/s41568-0…
Alan Meng retweeted
A patient-derived ovarian cancer organoid platform to study susceptibility to NK cells
doi.org/10.1101/2025.03.06.6…
Alan Meng retweeted
Simultaneous @NatureMedicine pub of 2 neoadjuvant chemo-IO trials for high-risk ER+ BC: KN-756 & CM-7FL. Both found a striking improvement in pCR rate with IO, with larger Δ if PD-L1+ or low ER. Waiting for EFS data, which will most likely impact practice. nature.com/articles/s41591-0…
Alan Meng retweeted
The CodeBreak 300 combination regimen is now approved in KRAS G12C #ColorectalCancer by @US_FDA
nejm.org/doi/full/10.1056/NE…
This Post is from an account that no longer exists. Learn more
Alan Meng retweeted
Reported associations between tumor-infiltrating lymphocyte subsets, including cytotoxic CD8+ T cells, CD4+ T helper cells, T reg cells & B cells in pretreatment tumor samples, and sensitivity or resistance to #immunotherapy in patients with various solid tumor types. nature.com/articles/s41571-0…
Alan Meng retweeted
Results from phase III ETOP 13 18 BEAT-meso trial @ESMO_Open. Adding atezolizumab to carboplatin + pemetrexed + bevacizumab improved PFS (HR 0.72) but no significant improvement in OS (20.5 vs 18.1m, HR 0.84). In non-epithelioid histology, OS HR 0.51.
annalsofoncology.org/article…
Alan Meng retweeted
Deletion of thrombospondin-1 prevents inflammaging and preserves blood stem cell fitness during aging
@SciImmunology @JMBstemcell
science.org/doi/10.1126/scii…
Alan Meng retweeted
🔥off the press:
The use of immunotherapy pre-liver transplant
@JHepatology
authors.elsevier.com/c/1kNgC…
👉Hepatology Snapshot
👉Our thoughts on the use of ICI before liver transplant in HCC
👉Food for thoughts..
@myESMO @EASLedu @ILCAnews #livertwitter
Alan Meng retweeted
Ginger is the No. 1 metabolism booster.
Consuming it daily can reduce cancer risk, support the immune system, and improve digestion.
Here’s how to consume it properly to avoid side effects (backed by science): 🧵
Readers added context they thought people might want to know
Claims are unverified, unproven, & exaggerated. While some studies suggest potential benefits, there is insufficient evidence to conclusively support these claims. Further research is needed to determine its true effectiveness.
medicalnewstoday.com/articles/265990
webmd.com/vitamins/ai/in…
Alan Meng retweeted
REVIEW: Harnessing the biology of regulatory T cells to treat disease
nature.com/articles/s41573-0…
@NatRevDrugDisc @mklevings @CM_Wardell
Alan Meng retweeted
The 3 year results of relativity 047 out in @JCO_ASCO .
Nivo+ relatlimab continues to impress.
Toxicity profile better than nivo ipi
Interestingly, at the 3 yr follow up, upper bound of HR 95% ci is less than 1 for overall survival
@samdoc_mamc
Alan Meng retweeted
🏥Liver Transplantation for Hepatocellular Carcinoma
@JCO_ASCO
✅Immunotherapy, local treatments and improved responses ➡️ expanding eligibility
❗️Challenges: Defining criteria, designing trials, biomarkers and organ shortage
@ArndtVogel @JCOOP_ASCO @ASCO @OncoAlert @realbowtiedoc #cancer #oncology #liver #MedX
Alan Meng retweeted
Impressive report in @NEJM. In a cohort of pregnant women with unusual clinical cfDNA-sequencing results, 52/107 were found to have a cancer via whole-body MRI, with a sensitivity of 98.0% and specificity of 88.5%. Physical exam & labs were of limited use. nejm.org/doi/full/10.1056/NE…
